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Abstract
Paromomycin (PMM) has recently been introduced for treatment of visceral leishmaniasis in India. Although no clinical
resistance has yet been reported, proactive vigilance should be warranted. The present in vitro study compared the
outcome and stability of experimental PMM-resistance induction on promastigotes and intracellular amastigotes. Cloned
antimony-resistant L. donovani field isolates from India and Nepal were exposed to stepwise increasing concentrations of
PMM (up to 500 mM), either as promastigotes or intracellular amastigotes. One resulting resistant strain was cloned and
checked for stability of resistance by drug-free in vitro passage as promastigotes for 20 weeks or a single in vivo passage in
the golden hamster. Resistance selection in promastigotes took about 25 weeks to reach the maximal 97 mM inclusion level
that did not affect normal growth. Comparison of the IC50 values between the parent and the selected strains revealed a 9
to 11-fold resistance for the Indian and 3 to 5-fold for the Nepalese strains whereby the resistant phenotype was also
maintained at the level of the amastigote. Applying PMM pressure to intracellular amastigotes produced resistance after just
two selection cycles (IC50 = 199 mM) compared to the parent strain (IC50 = 45 mM). In the amastigote-induced strains/clones,
lower PMM susceptibilities were seen only in amastigotes and not at all in promastigotes. This resistance phenotype
remained stable after serial in vitro passage as promastigote for 20 weeks and after a single in vivo passage in the hamster.
This study clearly demonstrates that a different PMM-resistance phenotype is obtained whether drug selection is applied to
promastigotes or intracellular amastigotes. These findings may have important relevance to resistance mechanism
investigations and the likelihood of resistance development and detection in the field.
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Introduction
Visceral leishmaniasis (VL) is a neglected and poverty-related
disease that causes significant morbidity and mortality. Treatment
options are quite limited and the development of resistance to
antimonials (Sb) has added to the problem [1]. To counter this
evolution, the Kala-Azar Elimination programme was officially
launched in India and Nepal in 2005 [2,3] and advocates the use
of miltefosine (MIL) as first-line alternative to Sb. However, other
drugs are still required for treating treatment failures.
The aminoglycoside antibiotic paromomycin (PMM) was shown
to be highly effective either as mono-therapy or in combination
with other drugs, be well-tolerated and currently the cheapest drug
available [4,5]. PMM has recently been licensed for the treatment
of VL in India as an injectable alternative to amphotericin B and
as a potential substitute for Sb [6]. It was shown that PMM is not
hampered by Sb-resistance [7], but appropriate measures should
certainly be taken to assure its long-term effectiveness. Resistance
in the field has not been reported yet, but this issue needs to be
proactively addressed in laboratory studies to help steer decisions
on future treatment policies, diagnosis and epidemiological
resistance monitoring.
Specific and stable resistance to PMM has experimentally been
induced in L. donovani promastigotes in vitro, providing initial basic
knowledge on putative PMM resistance mechanisms, character-
ized by an altered mitochondrial energy metabolism [8] and
reduced accumulation due to a significant reduction in initial
binding to the cell surface [9]. The resistant lines were still
infective to macrophages in vitro and for mice [10], raising
concerns about the transmission potential of resistant parasites.
These studies used laboratory strains which are well characterized
but may have diverged substantially from current field isolates and
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thus react differently to drug pressure [11]. More importantly,
resistance was induced on promastigotes that are not the relevant
stage subjected to natural drug pressure and in addition are
biochemically different from amastigotes, rendering their predic-
tive value at least questionable.
The aim of this study was to compare resistance-induction
protocols on promastigotes and intracellular amastigotes and use
cloned recent field isolates with a defined Sb-resistance back-
ground instead of drug-susceptible laboratory strains. The stability
of the ensuing PMM-resistant clones was subsequently checked in
vitro and in vivo.
Materials and Methods
Ethics statement
This study using laboratory rodents was carried out in strict
accordance with the guidelines that are in force in the countries of
the research partners and was approved by the ethical committees
the research institutes of the authors: a/University of Antwerp,
Belgium (UA) ECD 2010–17 (18-8-2010) and adopting the EC
Directive 2010/63/EU; b/National Institute of Pathology, India
(ICMR): Committee for the Purpose of Control and Supervision
on Experiments on Animals (CPCSEA), registration number 102-
1999/CPCSEA (28-4-1999), and c/University of Strathclyde, UK
(SU): UK Home Office project license number 60/3740.
Animals
Swiss mice (UA), age-matched in-house inbred BALB/c mice
(SU, ICMR) and golden hamsters (UA) were kept on a regular
rodent diet and given drinking water ad libitum. Mice were used to
collect primary peritoneal macrophages (MPM) as previously
described [12].
Parasite strains and standard culture
Clones of clinical isolates of L. donovani were used as parent strain
for drug selection and were obtained from the Institute of Tropical
Medicine Antwerp within the frame of the EC Kaladrug-R project:
MHOM/IN/09/BHU568/0 cl-1 and MHOM/IN/09/BHU573/
0 cl-3 from an endemic region in Bihar State India and within the
frame of the EC Leishnatdrug-R project: MHOM/NP/03/
BPK087/0 cl-11 and MHOM/NP/03/BPK275/0 cl-18 from an
endemic region in Nepal. The parent isolates were collected from
bone marrow aspirates of patients unresponsive to Sb treatment
(except BPK087/0 isolated from a patient that finally cured at 12
months follow-up) and typed as L. donovani based on a CPB-PCR-
RFLP assay [13]. Primary isolation of promastigotes was done on
Tobie’s blood agar medium at 26uC. In the laboratory, promas-
tigote cultures were maintained at room temperature in HOMEM
(Invitrogen) supplemented with 200 mM L-glutamine, 16.5 mM
NaHCO3, 10% heat-inactivated FCS and 40 mg/L adenine,
3 mg/L folic acid, 2 mg/L D-biotin and 2.5 mg/L hemin.. The
number of passages was kept as low as possible.
Antileishmanial reference drugs
Pure crystalline PMM (paromomycin-sulphate USP) was
obtained from Sigma-Aldrich or Gland Pharma, India. SbIII
(potassium antimonyl tartrate trihydrate) was purchased from
Sigma-Aldrich whereas MIL and SbV (sodium-stibogluconate)
were kindly provided by WHO-TDR. Because the SbIII and SbV
formulations contain different amounts of active constituent, their
concentration is expressed in equivalents (mg/ml eq.): 1 mg
potassium antimonyl tartrate trihydrate contains 0.361 mg SbIII
eq. and 1 mg sodium stibogluconate contains 0.313 mg SbV eq.
Stock solutions of SbIII and SbV were prepared in pre-heated PBS
at 37uC and stored at 220uC for max 3 months. MIL and PMM
were dissolved in MilliQ-water and stored at 4uC.
Resistance selection assay on promastigotes
Promastigotes of the four strains were passaged in vitro with a
stepwise increase in the concentration of PMM (8, 16, 32, 64 and
97 mM) in the HOMEM culture medium. Parasites were
considered adapted to the increased concentration when they
could grow at a same rate as the parent wild type parasite.
Adaptation was stopped at 97 mM as higher concentrations proved
to affect normal growth. During the stepwise induction of the
Indian strains, the intermediate stage parasites were also passaged
through (non-treated) macrophages (MPM, J774 cell line) to
maintain infectivity (Table 1).
Log-phase (day 4) promastigotes (100 ml parasite suspension)
were seeded into the wells of 96-well plates at 56105 parasites/well
and incubated with 100 ml medium alone (untreated con-
trols = 100% growth) or serial dilutions of PMM in medium. After
72-hour incubation at 25uC, 20 ml of a 0.0125% (w/v) resazurin
(Sigma-Aldrich) in PBS solution was added to each well and the
plates were incubated for a further 18 h after which cell viability was
measured fluorimetrically (lexc 550 nm; lem 590 nm). The results
are expressed as the percentage reduction in the parasite viability
compared to that in untreated control wells, and the 50% inhibitory
concentration (IC50) was calculated using Statview Software. All
experiments were performed at least twice in quadruplicates.
Resistance selection assay on intracellular amastigotes
Only the parent clone MHOM/NP/03/BPK275/0 cl-18 was
used for the resistance selection experiments on amastigotes. At
the start, the in vitro resistance profile against antimony (SbIII and
SbV), MIL and PMM had already been determined using
previously described methods [14]. In brief, the clone was highly
resistant to both SbV (IC50.77 mg/ml eq.) and Sb
III
(IC50 = 51.160.7 mg/ml eq.) and fully sensitive to MIL
(IC50 = 1.860.1 mM) and PMM (IC50 = 45.065.6 mM) (Table 2).
Author Summary
Leishmaniasis is caused by protozoan parasites of the
genus Leishmania and is transmitted by inoculation of
infective promastigotes by the female sand fly. In the
mammalian host, amastigotes live inside macrophage cells
which may lead to various clinical symptoms. First-line
treatment relies mainly on antimonials and miltefosine;
however, drug resistance is a growing problem. The
antibiotic paromomycin (PMM) has recently been added
as treatment option, but it is now essential to proactively
assess the likelihood of resistance development to
safeguard its long term effectiveness. Since ‘resistant’
patient isolates are not yet available, we artificially selected
for PMM resistance using two different in vitro protocols
with drug pressure on either the extracellular promasti-
gote or on the intracellular amastigote stage. Resistance in
promastigotes was obtained after about 25 weeks and
persisted in the intracellular amastigote. High levels of
resistance were obtained within two selection cycles on
amastigotes, but with the unexpected observation that the
promastigotes remained fully susceptible. In addition, the
resistance proved to be stable. We could clearly demon-
strate that a different PMM-resistance is obtained depen-
dent on the ‘stage-selection’ protocol. These findings have
important relevance to resistance mechanism investiga-
tions and the likelihood of resistance development and
detection in the field.
Paromomycin Resistance Selection in L. donovani
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The principle of the selection method (Fig. 1) was to maintain
the highest possible PMM drug pressure in successive cycles of
intracellular amastigotes, alternated with non-exposed promasti-
gote cycles to expand the selected population for the subsequent
infection. Prior experiments had already indicated that PMM is
well-tolerated by primary mouse macrophages up to 500 mM,
Table 1. PMM resistance selection in promastigotes: in vitro PMM susceptibility (IC50) of L. donovani parasites cultured as
promastigotes under increasing PMM drug pressure.
Strain/clone Selection Promastigote susceptibility Amastigote susceptibility
IC50 (mean ± sd)
IC50 (mean ± sd)
MPM J774
Indian strains
BHU568/0 cl-1 P 47614 961 1461
R 549693 5762 83611
BHU573/0 cl-3 P 3561 1161 1361
R 334625 6167 92612
Nepalese strains
BPK087/0 cl-11* P 4667 32612 nd
R 201617 9362 nd
BPK275/0 cl-18 P 5962 29615 nd
R 166624 13463 nd
To determine amastigote susceptibility of the induced promastigotes, stationary-phase stages were used to infect mouse primary macrophages and J774 macrophages.
P= parent non selected strain/R = selected resistant strain
nd = not done.
*BPK087/0 cl-11: susceptible to SbIII (IC50,15 mg/ml eq.) and resistant to SbV (IC50.77 mg/ml eq.)
doi:10.1371/journal.pntd.0001664.t001
Table 2. PMM resistance selection on intracellular amastigotes: in vitro susceptibility (IC50) of the parent strain and the selected
clones as promastigote and as intracellular amastigote to PMM, SbIII, SbV and MIL.
Strain Promastigote susceptibility (IC50) Amastigote susceptibility (IC50)
PMM (mM) SbIII (mg/ml eq.) MIL (mM) PMM (mM)
SbV (mg/ml
eq.) SbIII (mg/ml eq.) MIL (mM)
mean ± SEM mean ± SEM mean ± SEM mean ± SEM mean mean ± SEM mean ± SEM
BPK 275/0 cl18 parent 19.760.3 48.962.2 2.360.4 45.065.6 .77 51.160.7 2.260.8
PMM selection cycle 1 nd nd nd 130.867.9 .77 52.360.5 2.061.0
PMM selection cycle 2 17.260.7 31.661.7 4.660.6 199.068.5 .77 57.360.9 2.161.2
clone 1 19.261.1 36.463.2 5.960.6 417.4615.1 .77 61.460.7 4.261.3
clone 2 23.561.2 32.061.6 3.760.1 196.8611.2 .77 55.561.1 2.560.0
clone 3 20.960.9 30.561.7 4.060.3 213.067.3 .77 55.761.2 2.560.0
clone 4 20.960.7 24.161.5 5.261.3 157.069.6 .77 60.961.2 1.960.0
clone 5 22.661.4 31.861.6 3.560.1 129.7613.1 .77 42.462.6 1.160.0
clone 6 19.361.3 28.161.9 3.460.1 57.166.8 .77 nd nd
clone 7 17.660.8 27.861.1 3.160.0 154.0614.9 .77 51.861.5 2.960.0
clone 8 14.560.5 26.260.7 3.360.0 313.1614.3 .77 53.061.4 2.5 060.0
clone 9 16.660.5 39.361.3 4.660.8 132.569.0 .77 46.467.3 2.160.0
clone 10 18.861.2 23.862.2 3.460.0 164.1616.7 .77 55.761.2 1.560.0
clone 11 12.460.3 34.760.7 7.461.1 338.2610.6 .77 59.660.9 2.760.6
clone 12 11.860.2 43.263.2 6.462.5 171.365.7 .77 51.861.5 1.660.0
clone 13 11.960.2 34.960.7 3.460.8 310.2611.8 .77 53.261.9 2.560.0
clone 14 10.560.3 29.561.6 6.960.1 71.262.8 .77 48.761.7 2.260.1
Intracellular amastigotes were transformed back to the extracellular (without drug exposure) promastigote stage after each selection cycle. After selection cycle-2,
fourteen clones were obtained from the induced PMM-resistant promastigote population.
nd: not done.
doi:10.1371/journal.pntd.0001664.t002
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which became the upper in-test dose-range for selection. Late
stationary-phase promastigotes were used to infect primary mouse
macrophages grown in RPMI-1640 medium. After removing the
non-internalized parasites, the infected cells were exposed to PMM
serial 2-fold dilutions starting from 500 mM. During the whole
selection process, no Sb drug pressure was exerted. All tests were
carried out in two parallel 96-well plates and incubated at 37uC
and 5% CO2. Five days after infection, one plate was Giemsa-
stained to enumerate the intracellular parasite burdens, while the
medium in the second plate was replaced by HOMEM
promastigote growth medium after scraping the macrophages to
mechanically release amastigotes surviving the highest drug
concentration and allow back-transformation into promastigotes.
Once promastigote growth was observed in the wells, further
expansion was done in 25 ml tissue culture bottles at 25uC in
HOMEM promastigote medium until stationary growth phase
was reached. This population enriched in metacyclics was then
used for the next infection round of macrophages under PMM
pressure. After each selection cycle, the level of resistance was
determined using the standard intracellular amastigote suscepti-
Figure 1. Selection procedure for induction of PMM-resistance using intracellular L. donovani amastigotes. Late stationary-phase
promastigotes were used to infect primary mouse macrophages exposed to 2-fold PMM dilutions starting from 500 mM. After 5 days, surviving
intracellular amastigotes at the highest PMM concentration (checked after Giemsa staining on a duplicate plate) were allowed to transform back into
promastigotes by replacing the RPMI cell culture medium by MEM-based promastigote medium and incubation at room temperature for 1 week.
Next, the recovered promastigotes were expanded in 25 ml tissue culture bottles without PMM pressure and used to infect a new batch of primary
mouse macrophages for another cycle of selection.
doi:10.1371/journal.pntd.0001664.g001
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bility test [14]. The selection cycles were repeated until the
maximum level of resistance was reached. In the first selection
process promastigotes were exposed to levels of 62.5 mM PMM
and the second cycle promastigotes were collected out of 125 mM.
This PMM-selected strain was finally cloned for further follow-up
studies. When conducting this protocol without exposing the
internalized amastigotes to PMM pressure, no changes in PMM
susceptibility were found.
Cloning of the selected PMM-resistant strain
Since a single promastigote frequently fails to multiply, spent
growth medium was used to enhance the cloning efficiency
(unpublished observation). The spent medium was prepared by
collecting supernatant of a logarithmic-phase (3-day) promastigote
culture, centrifugation and filtration through a 0.22 mm filter. A
‘micro-drop’ method was used as cloning procedure. Briefly, an
appropriate ‘donor dilution’ of a 3-day old promastigote culture
was prepared from which the micro-drops were to be taken. In an
‘acceptor’ 96-well plate, 8 ml of HOMEM medium was placed to
the side of the well to avoid rapid evaporation of the micro-drop,
placed in the middle of the well with a fine needle by touching the
bottom of the well. The presence of drops with a single
promastigote was checked microscopically by two independent
observers and 100 ml spent medium+100 ml HOMEM culture
medium were added to the well. This procedure was continued
until all 96-wells of the ‘acceptor’ plate were complete. The
discarded wells with none or more than 1 promastigote were filled
with 200 ml water and the plate was wrapped in parafilm to avoid
evaporation. After incubation at 25uC for one week, growth was
microscopically checked and established clones were transferred to
a 25 ml tissue culture bottle for further routine culture. The in vitro
susceptibility against PMM, SbV, SbIII and MIL was evaluated for
each established clone, both as promastigote as well as intracellular
amastigote (Table 2).
In vitro and in vivo stability of PMM-resistance
The clones 1, 8, 11 and 13 were subjected to long term in vitro
drug-free sub-cultivation to evaluate the stability of the PMM-
resistant phenotype (Table 3). Routine sub-cultivation of promas-
tigotes was done twice weekly for 20 weeks with in vitro
susceptibility testing as intracellular amastigotes every two weeks.
The in vivo stability of the PMM-resistant phenotype was evaluated
by infecting hamsters with 26107 late-stationary promastigotes of
the respective clones. After eight weeks, a liver biopsy was taken
for microscopic estimation of the parasite burden. When the
biopsy revealed severe infection, the animal was sacrificed to
collect spleen-derived amastigotes that were used to run the
standard in vitro intracellular amastigote susceptibility assay and
determination of IC50 values.
Results
PMM resistance selection on promastigotes
The selection process for the Indian and the Nepalese strains
was very comparable and respectively took 32 weeks and 26 weeks
to reach the maximal 97 mM inclusion level of PMM that did not
affect normal growth. While the growth rate of the finally selected
strains proved to be fully comparable to that of parent non-
selected strains (growth curves not shown), comparison of the IC50
values between the parent and the resistance-selected strains
revealed large differences, being about 9 to 11-fold for the Indian
strains and about 3 to 5-fold for de Nepalese strains. Subsequent
evaluation in the macrophage susceptibility assay showed that the
resistant phenotype was maintained at the level of the amastigote,
although not in a linear manner. The differences between MPM
and J774 host cells were minimal (Table 1).
PMM resistance selection on amastigotes
High PMM drug pressure on intracellular amastigotes very
quickly selected for decreased susceptibility since already within
one cycle, PMM-susceptibility showed a .3-fold decrease
(IC50 = 130.8 mM), while the second selection cycle resulted into
an additional 1.4-fold decrease (IC50 = 199 mM) compared to the
parent source strain (IC50 = 45 mM) (Table 2). Additional selection
cycles did not result in any further significant increase of the IC50
(data not shown).
From the final PMM R-selected culture, 14 clones could be
established (Table 2). Subsequent susceptibility profiling revealed
that the population had become polyclonal during the selection
process with several clones being highly resistant to PMM with
tolerance levels up to 7 to 96 compared to the parent strain
(clones 1, 8, 11, 13), while a few others (clone 6 and 14) were still
fully susceptible. The remaining clones showed intermediate
susceptibility. The susceptibility to the other reference drugs
remained unchanged compared to the parent clone: full resistance
to SbV (IC50.77 mg/ml eq.) and Sb
III (IC50 range 42.4–61.4 mg/
ml eq.) and full susceptibility to MIL (IC50 range = 1.1–4.2 mM).
Quite surprisingly, promastigotes of all 14 clones remained fully
susceptible to PMM with IC50 values ranging between 10.5–
Table 3. Stability of PMM-resistance: in vitro IC50 after serial passage for 20 weeks as promastigotes or after passage in the hamster
and collection of spleen-derived amastigotes.
Strain Intracellular amastigote susceptibility assay: IC50 PMM (mM)
at induction in vitro passage (20weeks) in vivo passage
MEAN ± SEM MEAN ± SEM MEAN ± SEM
BPK275/0 cl 18 parent 45.065.6 58.561.5 75.368.3
BPK 275/0 PMM-R 199.068.5 82.564.3 nd
clone 1 417.4615.1 219.0630.6 520.9613.0
clone 8 313.1614.3 169.4613.8 291.5616.6
clone 11 338.2610.6 201.7616.8 182.064.0
clone 13 310.2611.8 268.9621.9 293.2616.1
nd: not done.
doi:10.1371/journal.pntd.0001664.t003
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23.5 mM, which sharply contrasts with the resistant amastigote
phenotype.
The stability of the resistant phenotype was checked for the non-
selected and selected parent strain and for the highly resistant
clones 1, 8, 11 and 13 adopting in vitro passage as promastigote for
20 weeks and by in vivo passage in the hamster (Table 3). The
promastigote susceptibility of the induced clones increased less
than 2-fold after 20 weeks. Passage in the hamster produced some
but minor variability in the IC50 values. Moreover, the Sb and
MIL in vitro phenotypes also remained unchanged (data not
shown).
Discussion
Paromomycin is currently considered as a promising new
antileishmania drug for the management of VL, and has already
been extensively studied in clinical trials for its potential as
monotherapy [15] or as combination therapy with antimonials
[16,17]. However, monotherapy holds a direct and enhanced risk
for the development of drug-resistance, and even combination
therapy is not devoid of risks particularly in foci where Sb-
resistance has already emerged. With regard to the latter, Bihar
State has become the primary testing ground for new therapeutic
approaches in VL [18]. For example, AmB is recommended as
first-line drug but this recommendation may fail to be implement-
ed in practice due to inadequate medical infrastructure [19,20].
The recently launched Kala-Azar elimination programme accom-
modates this by offering a fully integrated approach in which MIL
has obtained a place among the first-line treatment options [3].
Despite the fact that PMM has already been widely considered as
a valuable adjunct to current therapeutic options because of its
high efficacy and tolerability [6,21], yet relatively few studies
focused on emergence and epidemiological monitoring of resis-
tance. Hence, there is an immediate need to gain pro-active
knowledge about PMM-resistance in case monotherapy would
become more widely implemented in low endemic areas or as part
of combination therapy in high endemic areas. Since PMM-
resistant clinical isolates are not yet available, the present in vitro
laboratory study induced PMM-resistance experimentally, consid-
ering drug selection pressure on both the promastigote and the
intracellular amastigote stage. In view of its proven added value in
combination with antimonials [16] and because of the high
prevalence of Sb-resistant parasites in the region, clinical isolates
with established Sb-resistant background were used as parent
strains for selection.
Applying drug pressure to promastigotes in a stepwise manner
resulted in resistance after 26 to 32 weeks producing levels that
were 9 to 11-fold for the Indian strains and about 3 to 5-fold for de
Nepalese strains (Table 1). Similar to previous observations, the
resistant phenotype is maintained upon infection of macrophages,
although not in a linear fashion. The growth rates of the
susceptible and PMM-resistant promastigotes were fully compa-
rable (data not shown), which contrasts with literature data [10].
However, it is important to note that resistance data on
promastigotes should always be treated with some scepticism
since this is not the stage that will eventually become exposed to
the drug in addition to the ample evidence of their differences to
amastigotes, not only biochemically [22–24] but also for drug
susceptibility [25]. For this reason, a specific protocol needed to be
developed (Fig. 1) to exert drug selection pressure on the
intracellular amastigote that is the sole target in the vertebrate
host.
Quite unexpectedly and in contrast to our observations in
promastigotes, selection of resistance at the intracellular amasti-
gote level was rapidly achieved, with a maximum already being
obtained after just two selection cycles. This produced a
population that tolerated up to 4 times higher PMM concentra-
tions (19968.5 mM) compared to the original parent clone
(45.065.6 mM), although the PMM-selected parasites retained a
SbV, SbIII and MIL susceptibility profile that was similar to the
parental line (Table 2). Taking note of the fact that the parent
strain was fully resistant to SbV and SbIII and that some specific
changes such as phospholipid composition [26,27] and membrane
fluidity [28] have been described in Sb-resistant strains, further
work would be needed to explore if this could have influenced the
outcome of selection and whether this would have been different if
a fully Sb-sensitive strain would have been used. Anyhow, more
strains would deserve to be investigated for PMM resistance
induction potential.
The particular value of this ‘intracellular amastigote’ selection
protocol lies in the fact that it more closely mimics the conditions
as they develop in the field, namely drug pressure at the amastigote
level in the mammalian host and disruption of drug pressure at the
promastigote level in the vector. The very quick selection of PMM
resistance using this model may indeed be a worrying observation,
but the parasites were exposed to a huge selection pressure
(500 mM=308 mg/ml) which possibly may never occur under the
actual clinical use conditions of the drug. For example during the
standard treatment course at 15 mg/kg daily for 21 days, peak
plasma concentrations were obtained within about 30–90 minutes
with steady-state PMM concentrations of about 20 mg/ml [4].
Anyhow, these data provide strong and convincing evidence on
the propensity of rapid resistance development if PMM would be
used in monotherapy and endorse the stringent need for close
epidemiological monitoring.
Although the selection was initiated from a cloned parent strain,
the ensuing PMM-selected population had become polyclonal
again containing sub-clones of varying PMM susceptibility
(Table 2). Most clones showed comparable susceptibility to the
selected parent strain (IC50 = 130–213 mM), a few were more
resistant (clones 1, 8, 11, 13: IC50.300 mM) but a few were still
fully susceptible (clones 6, 14: IC50,72 mM). With regard to the
latter, it is difficult to explain how these susceptible clones were
able to persist in the parent population that was subjected to high
levels of PMM. Although yet never described for protozoa, one
might speculate on the existence of mixed phenotype ‘organized’
populations and ‘persisters’ as has been described for bacteria and
yeasts [29] or on the occurrence of multiple mutations as recently
described for L. major [30]. Consistent with the parent strain, all
clones remained susceptible to MIL and resistant to Sb, the latter
being related to the fact that resistance was selected against an
established SbV/SbIII-resistant (R/R) background.
Another probably more unexpected observation was that the
amastigote-induced resistant strain/clones only showed reduced
PMM susceptibility at the intracellular amastigote and not at all at
the promastigote stage, which sharply contrasts with the observa-
tions in the induced promastigotes that maintained the resistant
phenotype as amastigote upon infection of the macrophage. This
clearly demonstrates that induction of resistance may evolve
differently in axenic promastigotes compared to intracellular
amastigotes and hence supports the notion that the promastigote
susceptibility assay should be avoided for PMM resistance
monitoring purposes. This also triggers the question whether the
initial observations on the mode of action and resistance [8,9]
adequately cover the whole set of resistance mechanisms in the
amastigote since promastigotes were used in these studies. In the
absence of detailed mode-of-action studies, it remains difficult to
speculate on putative mechanisms.
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Finally, the stability of the induced PMM-resistance was
checked after in vitro serial passage for 20 weeks as promastigote
and after a single in vivo passage in the hamster (Table 3). Even
though a small decrease of PMM tolerance was observed after 20
weeks, the PMM-resistant phenotype persisted in the clones,
tolerating up to 36more PMM compared to the parent strain.
The IC50 of the parent strain itself dropped slightly back from
19968.5 mM to 82.564.3 mM (Table 2), suggesting that suscep-
tible organisms with higher fitness may have increased their
proportion in the passaged population after 20 weeks. Unfortu-
nately, the relative fitness of the different clones was not evaluated
in this study. More importantly, passage in the hamster did not
alter the drug susceptibility phenotype, although some minor
variation in PMM susceptibility was found. Even the Sb R/R
phenotype remained stable after all these manipulations.
Whether such a selection will actually occur in the field is still
unknown, but the speed and stability of the induced PMM
resistance certainly represents an area of concern, particularly
because the standard promastigote susceptibility assay may not
reveal the true situation in the field. More studies are now needed
to verify whether these in vitro findings bear direct relevance to the
epidemiological situation in areas where PMM is being used to
treat VL. Factors that also need to be taken into account are the
pharmacodynamics and -kinetics of PMM. The parasites induced
in this study were subjected to extreme high concentrations of
PMM far beyond the normal therapeutic plasma concentration.
This interpretation may on the one hand support the position that
induction/selection of PMM-resistance in the field may not
develop that quickly because of the lower selection pressure; on
the other hand, the pharmacodynamics and pharmacokinetics
within the macrophage host cell are largely unknown.
In conclusion, these observations strongly endorse the need to
adopt strong treatment policies to ensure long-term efficacy of
PMM. Stable PMM-resistant parasites could rapidly be induced in
vitro using a novel amastigote selection model that mimics more
closely the situation in the human patient. Whether the in vitro
phenotype translates to in vivo treatment failure upon PMM
treatment remains to be investigated, for example in the VL
hamster model. Other follow-up research should include L.
infantum and a larger number of strains, including Sb-susceptible
and MIL-resistant isolates.
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